Wills Eye Hospital in Philadelphia recently began a first phase-1 clinical research trial for a first-of-its kind treatment option for early-stage eye melanoma.
The treatment, called light-activated AU-011, was reportedly developed by Aura Biosciences. It is reportedly an investigational drug that targets and aims to selectively destroy malignant cancer cells in patients who have ocular melanoma.
The treatment approach now being investigated at Wills Eye Hospital reportedly uses viral nanoparticle conjugates, and involves injecting the AU-011 investigational drug into the eye affected by cancer followed by the brief use of a companion ophthalmic laser treatment to activate the drug. Researchers expect the drug to destroy the membranes of the ocular melanoma while sparing key eye structures, allowing for the potential of preserving patients’ vision.
According to Wills Eye Hospital, the trial began in early 2017 and is expected to enroll up to 12 patients at Wills and other clinical trial sites. Patients treated in the trial will be observed and followed for two years.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
Source: Wills Eye Hospital